Prostate cancer (PCa) is common, with it being the 2nd most prevalent cancer in men worldwide and the 6th leading cause of death in men. Screening for any type of cancer aims to increase the chances of successful treatment through early detection of the disease. There were some systematic reviews (SRs) evaluated the diagnostic value of biomarkers for the diagnosis of PCa and no studies have been conducted to analyze the quality of these SRs. We are not clear which kind of marker is the best choice. Thus, this study aims to assess the methodologic quality of the SRs and reanalyze the published data based on SRs for the biomarkers to find the optimal biomarker for the early diagnosis of PCa.

We performed a systematic literature search of PubMed, Embase, Web of Science, and Cochrane Library and to identify relevant SRs from inception to April 2019. Diagnostic accuracy studies included any type of single biomarker or combined biomarkers aimed at evaluating the diagnostic value is considered eligible for this overview. The Assessment of Multiple Systematic Reviews-2 (AMSTAR-2) instrument will be used to evaluate the risk of bias of the included SRs. Standard pairwise meta-analysis and adjusted indirect comparison will be used to compare the diagnostic value of different biomarkers.

The results of this study will be submitted to a peer-reviewed journal for publication.

This study will reanalyze the published data based on SRs. We hope that the results will help find a biomarker with the superior diagnostic performance for the diagnosis of PCa.


Medicine. 2019 Jul [Epub]

Junhai Jia, Yue Sun, Jingjie Ren, Muyang Li, Jiancheng Wang, Haiyang Li, Cancer Biomarker Assessment Working Group

Gansu Province Hospital Rehabilitation Center., School of Nursing, Lanzhou University., The Second Clinical Medical College of Lanzhou University., Hospital Management Research Center, Lanzhou University., Gansu Provincial Hospital, Lanzhou, Gansu Province, China.